SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is a focal point of discussion as a prominent influencer's audacious "three-digit" price prediction by year-end approaches its unfulfilled deadline, sparking considerable community mockery and frustration. Amidst this sentiment, traders are also discussing the upcoming monthly token unlock and anticipating potential catalysts like the Clarity Act in the coming year, while deeply divided on whether institutional interest signals an imminent supply shock or continued price manipulation.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto ($SAILANA) is actively trending as its 'Wolfpack' community rallies around the recently launched WolfSWAP, a cross-chain aggregator that facilitates token swaps and offers fee-sharing opportunities for other projects. Community members are enthusiastically discussing this innovative utility and anticipating a future 'flagship product' that they believe will establish Sailana as a leading, decentralized memecoin.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is trending as the crypto community intensely debates Bitcoin's near-term future, with many anticipating a "crypto winter" and substantial declines based on historical cycles. Conversely, a significant portion argues that institutional adoption and shifting market dynamics signal undervaluation and an impending "parabolic" rally. This sharp divergence underscores ongoing uncertainty about Bitcoin's valuation and whether traditional patterns will hold, making GBTC a focal point in the contrasting outlooks for digital assets.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending as the crypto market experiences notable outflows from Bitcoin ETFs, fueling a contentious community debate. A significant portion warns of an impending "crypto winter" and further declines, referencing past cycles and the absence of a blow-off top. Conversely, others maintain a long-term bullish stance, citing Bitcoin's historical resilience and sustained institutional interest.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amidst a polarized community debate on Bitcoin's price trajectory, with market participants closely watching the upcoming Bank of Japan rate decision as a key catalyst. Many are actively discussing whether Bitcoin has entered a 'crypto winter,' citing historical cycles and portraying recent price movements as opportunities for large holders to exit, while others highlight sustained institutional interest and ETF inflows as bullish indicators.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins ($PENGU) is actively trending due to its ambitious real-world integrations, highlighted by its high-profile appearance on the Las Vegas Sphere and partnerships with the NHL, Care Bears, and DreamWorks' Kung Fu Panda. While many in the community are debating significant recent price drops and labeling it a 'scam,' others are accumulating, citing these unique brand collaborations as strong long-term fundamentals that could propel the meme coin higher, particularly with ongoing speculation about a potential ETF approval.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amidst a highly divided community, with proponents highlighting its real-world utility through Flexa partnerships and potential positive impacts from the Clarity Act and rumored mergers. While some anticipate significant upward movement, a vocal segment expresses deep frustration over past performance and skepticism, labeling it a 'scam' due to perceived manipulation and persistent downward pressure.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is surging due to the FDA granting Priority Review for its AXS-05 supplemental New Drug Application for Alzheimer's disease agitation, signaling an accelerated review timeline. This significant regulatory clarity, coupled with positive pre-NDA feedback for AXS-12 in narcolepsy, has ignited widespread excitement among long-term investors. The community is actively discussing the stock's substantial price and volume increase, viewing these developments as a major validation for Axsome's robust CNS pipeline within the dynamic biotech sector.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending significantly due to a strategic manufacturing partnership announcement aimed at scaling production of its drug screening reader for future U.S. market entry. This news, combined with the stock's low float, generated immense trading volume and fueled speculation about a short squeeze. However, community sentiment is highly divided following an after-hours private placement offering with warrants, which introduced dilution concerns after the initial surge.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a hot topic as the market weighs a significant price drop and the FDA's approval of Novo Nordisk's oral Wegovy, fueling speculation about a distribution partnership. Bulls view current levels as a strong buying opportunity, citing robust subscriber growth and a share buyback program. Meanwhile, bears express concern over valuation, perceived market manipulation, and the company's long-term competitive position in the direct-to-consumer health sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evofem Biosciences&nbsp;Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt&nbsp;Companies Targeting Closing in Fourth Quarter of 2024&nbsp;Mountain View, CA., September 24, 2024 —&nbsp;Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target,&nbsp;Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a&nbsp;<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318604913&amp;type=HTML&amp;symbol=EVFM&amp;cdn=aa965ae7d29bd4fb48009ea93f2217c9&amp;companyName=Evofem+Biosciences+Inc.&amp;formType=PRE+14A&amp;dateFiled=2024-09-23">preliminary proxy</a> to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the “Merger Agreement”), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt (“Adifem”), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024.&nbsp;No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.&nbsp;About Evofem Biosciences, Inc.Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexxi.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=Phexxi%26%23174%3B+%28lactic+acid%2C+citric+acid+and+potassium+bitartrate%29&amp;index=1&amp;md5=3e729597ceeb7cf85250cc4e87c1ad26">Phexxi&nbsp;®&nbsp;(lactic acid, citric acid and potassium bitartrate)&nbsp;</a>, is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.In July 2024, Evofem broadened its commercial offering with the acquisition of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solosec.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=2&amp;md5=f57d1d7baa215b526187a6b94e5c1456">SOLOSEC® (secnidazole) 2g oral granules&nbsp;</a>, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose.&nbsp;Follow us on: LinkedIn:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem&amp;index=3&amp;md5=d02dd9371f079a9ddf3d4b4c14e86d11">https://www.linkedin.com/company/evofem</a> Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;index=4&amp;md5=7479074d1930b4c67c3da4c67775fd95">http://www.facebook.com/Evofem</a> X (f/k/a Twitter):&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FEvofem&amp;index=5&amp;md5=27b4287d506408c08aa627eaa266acdc">https://x.com/Evofem</a>Phexxi&nbsp;®&nbsp;and SOLOSEC&nbsp;®&nbsp;are registered trademarks of Evofem Biosciences, Inc.&nbsp;About Aditxt, Inc.Aditxt, Inc.®&nbsp;is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.&nbsp;Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.For more information,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aditxt.com&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=www.aditxt.com&amp;index=4&amp;md5=d821cbe54c4f57eac0b1c374c9688090">www.aditxt.com</a>.Follow us on:LinkedIn:&nbsp;<a href="https://www.linkedin.com/company/aditxt">https://www.linkedin.com/company/aditxt</a>&nbsp; Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;index=6&amp;md5=44180bd3ab05184be51a0d6dec9d979b">https://www.facebook.com/aditxtplatform/</a>&nbsp;Forward-Looking StatementsCertain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&amp;A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.&nbsp;Additional Information and Where to Find ItThis communication may be deemed to be solicitation material in respect of the proposed transactions. In connection with the proposed transactions, a proxy statement of Evofem Biosciences, Inc. and other materials will be filed with the SEC. WE URGE INVESTORS TO READ THE PROXY STATEMENT AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EVOFEM BIOSCIENCES, INC. AND THE PROPOSED TRANSACTIONS. Investors will be able to obtain free copies of the proxy statement (when available) as well as other filed documents containing information about Evofem Biosciences, Inc. on the SEC’s website at http://www.sec.gov. Free copies of Evofem Biosciences’ SEC filings are also available from Evofem Biosciences, Inc., 7770 Regents Road, Suite 113-618, San Diego, California 92122, Attention: Corporate Secretary.&nbsp;Participants in the SolicitationEvofem Biosciences and its executive officers, directors, other members of management, employees and Evofem Biosciences may be deemed, under SEC rules, to be participants in the solicitation of proxies from Evofem Biosciences’ stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of Evofem Biosciences is set forth in its definitive proxy statement for its special meeting. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transactions.&nbsp;ContactAditxt, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mary O’Brien&nbsp;<a href="mailto:Mobrien@aditxt.com">Mobrien@aditxt.com</a>(516) 753-9933

Evofem Biosciences  Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt and Evofem file a preliminary proxy for stockholder approval of their merger, targeting a Q4 2024 closing. The merger aims to expand innovative women’s health solutions.

Aditxt and Evofem Seek Approval for Merger, Closing Expected Q4 2024

Equity

Aditxt and Evofem file for stockholder approval to finalize their merger in Q4 2024. The acquisition will position Evofem as a wholly owned Aditxt subsidiary, enhancing their women’s health portfolio.

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

EVFM
Evofem Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EVFM News

EVFMEvofem Biosciences Inc